Therapeutic effect of positron emission tomography agent 18F-FDG on MCF-7 in nude mice

QinFeng Xu,Wanhua Guo,Aimei Li,XiaWen Lin,ZhiJun Jia
2012-01-01
Abstract:[Objective] To study the therapeutic potential of PET agent [18F] labeled 2-deoxy-2-fluoro-D-glucose (18F-FDG) to MCF-7 in nude mice and its molecular mechanism. [Methods] The breast cancer cell line MCF-7 was cultured with 18F-FDG in different doses (0-7.4 × 106 Bq/mL). The γ-ray high energy counting machine was used to detect uptake of γ-ray by MCF-7 cells. The MCF-7 cells were inoculated in nude mice. The tumor-bearing mice were treated with normal saline, 3.7 MBq, 11.1 MBq and 37 MBq 18F-FDG, respectively. Dynamic changes of xenogafts volume were calculated. Then these mice were imaged by microPET with 18F-FDG. Tumors were analyzed for expression of cleaved CASPASE-3 and BCL-2 by western blot. [Results] In vitro uptake of 18F-FDG by MCF-7 cells was linear dose dependence. All treatment groups showed significant reduction of tumor growth rate compared with the control group (P < 0.05). The rate of tumor growth was lower in groups of higher treatment dose (11.1 MBq and 37 MBq) than in group of lower treatment dose (3.7 MBq). Images of microPET showed that the concentration of 18F-FDG was lower in tumor site of treatment groups than that in control group, and it was decreasing with the increasing of treatment dose. The expression levels of cleaved CASPASE-3 in treatment groups (3.7 MBq, 11.1 MBq and 37 MBq) were significantly higher than that in the control group (4.935 ± 1.521, 5.560 ± 1.459, 2.138 ± 0.844 vs 0.019 ± 0.049) (P < 0.05 or P < 0.01), while the expression levels of BCL-2 were significantly lower in treatment groups than that in the control group (1.489 ± 0.691, 1.929 ± 0.949, 3.421 ± 1.554 vs 5.143 ± 1.813) (P < 0.05 or P < 0.01). There were no significant difference in the expression levels of BCL-2 and cleaved CASPASE-3 between 11.1 MBq and 37 MBq group (P > 0.05), but the expression levels of BCL-2 in the two groups were both lower than that in 3.7 MBq group (P < 0.05), and the expression levels of cleaved CASPASE-3 were higher than that in 3.7 MBq group (P < 0.05). [Conclusions] The study suggested that 18F-FDG had a therapeutic effect in breast cancer by decreasing of BCL-2 expression and increasing of cleaved CASPASE-3 expression.
What problem does this paper attempt to address?